PitSTOP
Start date:August 2017 End date:
August 2018 Co-ordinated by:
Dr John Emelifeonwu and the EMERGE Team, RIE Main trial site:
RIE
Primary Objective
To determine the prevalence of anterior pituitary gland dysfunction in traumatic brain injury in Scotland.
Secondary Objectives
To determine whether clinical and radiologically parameters available on presentation can predict likelihood of developing PTPD in patients with TBI.
To determine the optimal timing after TBI for blood tests to diagnose PTPD
To determine whether PTPD effects functional recovery as determined by the extended Glasgow Outcome Score (eGOS)
Chief Investigator
Dr John Emelifeonwu
Surgical Trainee, Clinical Neurosciences
Research Team
Mia Paderanga
Senior Research Nurse
Julia Grahamslaw
Lead Research Nurse
More EMERGE Trials
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
NOVEL Study
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.